---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-25-000014"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:36:33.939212+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027

## Summary
- Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.
- Net income $3.6M in 2024 vs net loss $12.5M in 2023; Q4 2024 net loss $4.2M.
- Received approval for KLARITY (Phase 2 KIO-104) and ABACUS-2 (Phase 2 KIO-301) studies.
- Recognized $16M in collaboration revenue from Laboratoires Théa for KIO-301 in 2024.
- Data readouts from both Phase 2 trials expected in 2026; first patient dosing in Q2 2025 for KLARITY.

## SEC filing metadata
- accession: 0001372514-25-000014
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/0001372514-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/kprx-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-25-000014
- JSON: https://secwatch.observer/filing/0001372514-25-000014.json
- Plain text: https://secwatch.observer/filing/0001372514-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.